A Long-term Follow-up of the HIV-NAT Cohort

Primary Objective:

To collect and evaluate long-term clinical outcomes of HIV infected participants previously enrolled in HIV-NAT trials.

Secondary Objective:

To Assess:

• Long-term consequences of initiation of antiretroviral as predicted by baseline CD4 cell count and/or baseline plasma HIV RNA level
• Incidence of lipodystrophy and other metabolic complications in three different groups of patients initially treated with NRTI-based regimens, NNRTI-based regimens, or PI-based regimens
• Class-specific incidence of lipodystrophy and metabolic complications such as d4T versus AZT, nevirapine versus efavirenz and individual PIs (IDV, SQV, Kaletra, and atazanavir)
• Resistance profiles in patients on different antiretroviral regimens
• Long-term consequences of antiretroviral agents on cardiovascular, renal, hepatic, and endocrine function, skin, gastrointestinal system and urogentital tract
• Incidence of opportunistic infections or malignancy including hepatocarcinoma in patients with HIV/HCV or HIV/HBV co-infection
• Immune recovery syndrome
• Adherence to different antiretroviral regimens
• Quality of life

Inclusion criteria

• HIV infected patients( children and adults) previously participated HIV-NAT studies
• HIV infected patients( children and adults) currently participate in HIV-NAT trials
• Able to provide written consent

Exclusion criteria

• Unable to provide written consent